Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.


Another Voice: Benefit managers contribute to high drug prices

DATE: April 24, 2017

Published by The Buffalo News

For a professor of pharmaceutical ethics, John Jones’ recent Another Voice column, “Blame drugmakers for high-priced drugs,” is a disappointing example of the kind of ethical blindness that has left our health care system with the problem of insanely high drug costs.

There is no doubt that drugmakers share the blame for high drug prices. But they are just one part of a larger drug system that is broken. If our country truly wants to lower drug prices, then it should take a long hard look at the role played by pharmacy benefit managers (PBMs).

It is no longer a secret that PBMs are a dominant player in the U.S. health care system. Today, just three PBMs control prescription drug benefits for 80 percent of Americans. They make billions of dollars in profits as middlemen in our health care system while delivering no actual patient care. In fact, what they do to the patients forced to use them often feels like just the opposite.
Every day my inbox is flooded with pleas for help from cancer clinics across the country struggling to help patients stuck in the bureaucratic purgatory of PBMs.

Medication delays that often last over a month, denials of lifesaving treatments and endless hours spent on the phone with unaccountable PBM representatives are the norm, not the exception.

Stuck in the middle of all this are very real and sick Americans who just want to get better.

PBMs argue that the rebates they get from pharmaceutical companies help control drug prices. What they refuse to disclose is how much (or how little) of those savings are passed on to patients. In fact, it might surprise some to know that PBMs have been waging a tone-deaf battle to avoid disclosing where those rebates go and who benefits – all while pointing the finger at everyone else in the system.

Additionally, PBMs fail to acknowledge the economic fact that discounts always get priced into prices. So, as they extract higher and higher discounts from drugmakers they are just driving drug prices higher.

Worse yet, because PBMs make percentage-based fees from pharmacies, they have a perverse incentive to keep drug prices high.

PBMs are not innocent bystanders – they are a direct cause of high drug prices. Yet, when it comes time to finding solutions, all PBMs do is point fingers.
It is time to drop the charade and address this head on. We need more transparency and accountability from PBMs and we need it now.

Ted Okon is executive director of the Community Oncology Alliance, a non-profit dedicated solely to preserving and protecting access to community cancer care, where the majority of Americans with cancer are treated.

Click here to see the original article on The Buffalo News website.

 

Recent Posts

Stay in the Know

Get the latest news and updates on issues impacting the long-term pharmacy community.

See Latest Updates